Shenzhen Kangtai Biological Products Co., Ltd.

XSEC:300601 Stock Report

Market Cap: CN¥21.3b

Shenzhen Kangtai Biological Products Valuation

Is 300601 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300601 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300601 (CN¥19.04) is trading below our estimate of fair value (CN¥59.56)

Significantly Below Fair Value: 300601 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300601?

Key metric: As 300601 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 300601. This is calculated by dividing 300601's market cap by their current earnings.
What is 300601's PE Ratio?
PE Ratio41.3x
EarningsCN¥515.35m
Market CapCN¥21.27b

Price to Earnings Ratio vs Peers

How does 300601's PE Ratio compare to its peers?

The above table shows the PE ratio for 300601 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average56.3x
300294 China Resources Boya Bio-pharmaceutical GroupLtd
87.5x44.4%CN¥15.4b
603087 Gan & Lee Pharmaceuticals
48.3x43.2%CN¥27.7b
002007 Hualan Biological Engineering
23.5x18.7%CN¥31.1b
688363 Bloomage BioTechnology
66.1x34.7%CN¥29.0b
300601 Shenzhen Kangtai Biological Products
41.3x39.8%CN¥21.3b

Price-To-Earnings vs Peers: 300601 is good value based on its Price-To-Earnings Ratio (41.3x) compared to the peer average (54.9x).

Price to Earnings Ratio vs Industry

How does 300601's PE Ratio compare vs other companies in the CN Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
300601 41.3xIndustry Avg. 36.6xNo. of Companies6PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 300601 is expensive based on its Price-To-Earnings Ratio (41.3x) compared to the CN Biotechs industry average (36.4x).

Price to Earnings Ratio vs Fair Ratio

What is 300601's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300601 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio41.3x
Fair PE Ratio39.4x

Price-To-Earnings vs Fair Ratio: 300601 is expensive based on its Price-To-Earnings Ratio (41.3x) compared to the estimated Fair Price-To-Earnings Ratio (39.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 300601 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥19.04
CN¥23.30
+22.4%
23.5%CN¥33.69CN¥16.64n/a6
Nov ’25CN¥18.26
CN¥22.15
+21.3%
28.5%CN¥33.69CN¥15.00n/a6
Oct ’25CN¥19.57
CN¥22.31
+14.0%
28.6%CN¥33.69CN¥15.00n/a6
Sep ’25CN¥14.42
CN¥23.79
+65.0%
23.6%CN¥33.69CN¥16.00n/a6
Aug ’25CN¥15.66
CN¥25.64
+63.7%
22.8%CN¥33.69CN¥16.00n/a5
Jul ’25CN¥15.92
CN¥30.72
+92.9%
15.9%CN¥37.40CN¥24.49n/a6
Jun ’25CN¥18.25
CN¥31.40
+72.0%
19.0%CN¥41.50CN¥24.49n/a6
May ’25CN¥20.20
CN¥35.68
+76.6%
15.7%CN¥46.00CN¥29.00n/a5
Apr ’25CN¥22.59
CN¥36.94
+63.5%
12.1%CN¥46.00CN¥32.89n/a6
Mar ’25CN¥24.25
CN¥36.94
+52.3%
12.1%CN¥46.00CN¥32.89n/a6
Feb ’25CN¥21.08
CN¥36.94
+75.2%
12.1%CN¥46.00CN¥32.89n/a6
Jan ’25CN¥27.15
CN¥36.94
+36.1%
12.1%CN¥46.00CN¥32.89n/a6
Dec ’24CN¥33.53
CN¥36.94
+10.2%
12.1%CN¥46.00CN¥32.89n/a6
Nov ’24CN¥30.20
CN¥36.92
+22.3%
12.1%CN¥46.00CN¥32.00CN¥18.267
Oct ’24CN¥29.27
CN¥38.39
+31.2%
13.5%CN¥49.60CN¥32.89CN¥19.577
Sep ’24CN¥27.72
CN¥39.31
+41.8%
12.8%CN¥49.60CN¥35.00CN¥14.426
Aug ’24CN¥29.26
CN¥40.71
+39.1%
16.4%CN¥55.00CN¥35.00CN¥15.666
Jul ’24CN¥25.39
CN¥42.54
+67.5%
13.4%CN¥55.00CN¥38.68CN¥15.926
Jun ’24CN¥28.08
CN¥42.54
+51.5%
13.4%CN¥55.00CN¥38.68CN¥18.256
May ’24CN¥30.31
CN¥42.54
+40.3%
13.4%CN¥55.00CN¥38.68CN¥20.206
Apr ’24CN¥31.64
CN¥48.05
+51.9%
16.0%CN¥60.00CN¥40.61CN¥22.594
Mar ’24CN¥34.47
CN¥46.41
+34.6%
16.4%CN¥60.00CN¥39.85CN¥24.255
Feb ’24CN¥37.28
CN¥46.41
+24.5%
16.4%CN¥60.00CN¥39.85CN¥21.085
Jan ’24CN¥31.53
CN¥45.81
+45.3%
17.6%CN¥60.00CN¥39.00CN¥27.155
Dec ’23CN¥34.15
CN¥45.81
+34.1%
17.6%CN¥60.00CN¥39.00CN¥33.535
Nov ’23CN¥33.93
CN¥45.81
+35.0%
17.6%CN¥60.00CN¥39.00CN¥30.205

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥47.5b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥31.84

7D

-3.9%

1Y

14.4%

Dong-E-E-JiaoLtd

CN¥37.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥58.44

7D

-2.0%

1Y

18.4%

China Resources Double-Crane PharmaceuticalLtd

CN¥22.3b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥21.72

7D

-1.2%

1Y

18.8%